Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapFalling Star
    All News

    Brief: TIVDAK® (Tisotumab Vedotin) Approved By Japan Ministry Of Health, Labour And Welfare For Treatment Of Advanced Or Recurrent Cervical Cancer That Has Progressed On Or After Chemotherapy

    Picture of Genmab A/S logoGenmab A/S
    27/03/2025 12:27
    March 27 (Reuters) - Genmab A/S GMAB.CO:

TIVDAK® (TISOTUMAB VEDOTIN) APPROVED BY JAPAN MINISTRY OF HEALTH, LABOUR AND WELFARE FOR TREATMENT OF ADVANCED OR RECURRENT CERVICAL CANCER THAT HAS PROGRESSED ON OR AFTER CHEMOTHERAPY

Source text: ID:nBw6TZrMNa

Further company coverage: GMAB.CO

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Genmab A/S

    See all news